<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666276</url>
  </required_header>
  <id_info>
    <org_study_id>A5951142</org_study_id>
    <nct_id>NCT00666276</nct_id>
  </id_info>
  <brief_title>Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)</brief_title>
  <official_title>Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug use investigation of Zyvox for patients with Methicillin-resistant Staphylococcus aureus
      (MRSA) infection disease.

      The objective of this surveillance is to collect information about 1) adverse drug reaction
      not expected from the Package Insert (unknown adverse drug reaction), 2) the incidence of
      adverse drug reactions in this surveillance, and 3)factors considered to affect the safety
      and/or efficacy of this drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the patients whom an investigator prescribes the first Linezolid should be registered
      consecutively until the number of subjects reaches target number in order to extract patients
      enrolled into the investigation at random.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction Not Expected From the Japanese Package Insert.</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>The adverse drug reaction that have not been listed in Japanese package insert.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Drug Reactions(ADRs).</measure>
    <time_frame>8 weeks</time_frame>
    <description>All observed or volunteered adverse events and the investigator's opinion of the causal relationship to the study treatment were reported. Adverse Drug Reactions were evaluated in company with the causal relationship to the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors Considered to Affect the Safety of Linezolid - Gender.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of participants with adverse drug reaction to determine whether male or female is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors Considered to Affect the Safety of Linezolid - Age</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of participants with adverse drug reaction to determine whether over 65 or less than 65 is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors Considered to Affect the Safety of Linezolid - Hepatic Dysfunctions.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of participants with or without Hepatic dysfunctions with adverse drug reaction to determine whether with or without is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors Considered to Affect the Safety of Linezolid - Renal Dysfunctions.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of participants with or without Renal dysfunctions with adverse drug reaction to determine whether with or without is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors Considered to Affect the Safety of Linezolid - Duration of Drug Administration.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of participants with Duration of drug administration as over 15 days or less than 15 days with adverse drug reaction to determine whether over 15 days or less than 15 days is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors Considered to Affect the Safety of Linezolid - Route of Administration.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of participants Route of administration as by oral,injection or oral from injection with adverse drug reaction to determine whether oral, injection or switch is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors Considered to Affect the Safety of Linezolid - Weight.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of participants Weight as over 40kg or less than 40kg with adverse drug reaction to determine whether over 40kg or less than 40kg Weight is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors Considered to Affect the Safety of Linezolid - Concomitant Drugs.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of participants with or without Concomitant drugs with adverse drug reaction to determine whether with or without is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors Considered to Affect the Safety of Linezolid - Non-drug Therapies.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of participants with or without Non-drug therapies with adverse drug reaction to determine whether with or without is significant risk factor.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1004</enrollment>
  <condition>Staphylococcal Infections</condition>
  <arm_group>
    <arm_group_label>linezolid (Zyvox)</arm_group_label>
    <description>Patients taking Linezolid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linezolid (Zyvox)</intervention_name>
    <description>Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.
Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration.</description>
    <arm_group_label>linezolid (Zyvox)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients whom an investigator involving A5951142 prescribes the Linezolid.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients need to be administered Linezolid in order to be enrolled in the
             surveillance.

        Exclusion Criteria:

          -  Patients not administered Linezolid.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5951142&amp;StudyName=Drug%20Use%20Investigation%20Of%20Zyvox%20%28Linezolid%29%20%28Regulatory%20Post%20Marketing%20Commitment%20Plan%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <results_first_submitted>March 28, 2012</results_first_submitted>
  <results_first_submitted_qc>May 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2012</results_first_posted>
  <last_update_submitted>May 29, 2012</last_update_submitted>
  <last_update_submitted_qc>May 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was an open label, prospective, multi-center non-interventional cohort study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Linezolid</title>
          <description>Participants who have been treated with Linezolid.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1004"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="970"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Linezolid</title>
          <description>Participants who have been treated with Linezolid.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="970"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Target disease</title>
          <description>The physician in charge of the study made the diagnosis of Target disease based on symptoms.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sepsis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deep-seated skin infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary infection in injury, Burn and operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Target disease Severity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Complications</title>
          <description>Complications is the patient's current experiences with illnesses, operations, injuries and treatments. The physician of this survey made the diagnosis. (e.g. hypertension, diabetes, etc.)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Drug Reaction Not Expected From the Japanese Package Insert.</title>
        <description>The adverse drug reaction that have not been listed in Japanese package insert.</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Participants who have been treated with Linezolid.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction Not Expected From the Japanese Package Insert.</title>
          <description>The adverse drug reaction that have not been listed in Japanese package insert.</description>
          <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="970"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Superinfection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactic acidosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deep vein thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperbilirubinaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antithrombin III decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood chloride increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood sodium increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Drug Reactions(ADRs).</title>
        <description>All observed or volunteered adverse events and the investigator’s opinion of the causal relationship to the study treatment were reported. Adverse Drug Reactions were evaluated in company with the causal relationship to the investigational product.</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Participants who have been treated with Linezolid.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reactions(ADRs).</title>
          <description>All observed or volunteered adverse events and the investigator’s opinion of the causal relationship to the study treatment were reported. Adverse Drug Reactions were evaluated in company with the causal relationship to the investigational product.</description>
          <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="970"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Factors Considered to Affect the Safety of Linezolid - Gender.</title>
        <description>Number of participants with adverse drug reaction to determine whether male or female is significant risk factor.</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid-male</title>
            <description>Male participants who have been treated with Linezolid.</description>
          </group>
          <group group_id="O2">
            <title>Linezolid-female</title>
            <description>Female participants who have been treated with Linezolid.</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Safety of Linezolid - Gender.</title>
          <description>Number of participants with adverse drug reaction to determine whether male or female is significant risk factor.</description>
          <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="662"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Gender&quot;. The null hypothesis is there is no difference between &quot;males and females&quot; in the incidence rate of ADRs.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.712</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Factors Considered to Affect the Safety of Linezolid - Age</title>
        <description>Number of participants with adverse drug reaction to determine whether over 65 or less than 65 is significant risk factor.</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid-over 65</title>
            <description>Participants with over 65 years old who have been treated with Linezolid.</description>
          </group>
          <group group_id="O2">
            <title>Linezolid-less Than 65</title>
            <description>Participants with less than 65 years old who have been treated with Linezolid.</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Safety of Linezolid - Age</title>
          <description>Number of participants with adverse drug reaction to determine whether over 65 or less than 65 is significant risk factor.</description>
          <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="688"/>
                <count group_id="O2" value="282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Age&quot;. The null hypothesis is there is no difference between &quot;over 65 and less than 65&quot; in the incidence rate of ADRs.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.257</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Factors Considered to Affect the Safety of Linezolid - Hepatic Dysfunctions.</title>
        <description>Number of participants with or without Hepatic dysfunctions with adverse drug reaction to determine whether with or without is significant risk factor.</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid-without Hepatic Dysfunctions</title>
            <description>Participants with or without Hepatic dysfunctions who have been treated with Linezolid.</description>
          </group>
          <group group_id="O2">
            <title>Linezolid- With Hepatic Dysfunctions</title>
            <description>Participants with Hepatic dysfunctions who have been treated with Linezolid.</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Safety of Linezolid - Hepatic Dysfunctions.</title>
          <description>Number of participants with or without Hepatic dysfunctions with adverse drug reaction to determine whether with or without is significant risk factor.</description>
          <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="856"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Hepatic dysfunctions&quot;. The null hypothesis is there is no difference between &quot;with Hepatic dysfunction and without Hepatic dysfunction&quot; in the incidence rate of ADRs.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.082</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Factors Considered to Affect the Safety of Linezolid - Renal Dysfunctions.</title>
        <description>Number of participants with or without Renal dysfunctions with adverse drug reaction to determine whether with or without is significant risk factor.</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid Without Renal Dysfunctions</title>
            <description>Participants without Renal dysfunctions who have been treated with Linezolid.</description>
          </group>
          <group group_id="O2">
            <title>Linezolid- With Renal Dysfunctions</title>
            <description>Participants with Renal dysfunctions who have been treated with Linezolid.</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Safety of Linezolid - Renal Dysfunctions.</title>
          <description>Number of participants with or without Renal dysfunctions with adverse drug reaction to determine whether with or without is significant risk factor.</description>
          <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="765"/>
                <count group_id="O2" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Renal dysfunctions&quot;. The null hypothesis is there is no difference between &quot;with Renal dysfunction and without Renal dysfunction&quot; in the incidence rate of ADRs.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.462</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Factors Considered to Affect the Safety of Linezolid - Duration of Drug Administration.</title>
        <description>Number of participants with Duration of drug administration as over 15 days or less than 15 days with adverse drug reaction to determine whether over 15 days or less than 15 days is significant risk factor.</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid-administrated Over 15 Days</title>
            <description>Participants who have been treated with Linezolid.with Duration of drug administration over 15 days</description>
          </group>
          <group group_id="O2">
            <title>Linezolid-administrated Less Than 15 Days</title>
            <description>Participants with who have been treated with Linezolid.with Duration of drug administration less than 15 days</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Safety of Linezolid - Duration of Drug Administration.</title>
          <description>Number of participants with Duration of drug administration as over 15 days or less than 15 days with adverse drug reaction to determine whether over 15 days or less than 15 days is significant risk factor.</description>
          <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="767"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Duration of drug administration&quot;. The null hypothesis is there is no difference between &quot;over 15 days and less than 15 days&quot; in the incidence rate of ADRs.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Factors Considered to Affect the Safety of Linezolid - Route of Administration.</title>
        <description>Number of participants Route of administration as by oral,injection or oral from injection with adverse drug reaction to determine whether oral, injection or switch is significant risk factor.</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid-oral</title>
            <description>Participants with who have been orally treated with Linezolid.</description>
          </group>
          <group group_id="O2">
            <title>Linezolid-injection</title>
            <description>Participants with who have been treated with Linezolid by injection.</description>
          </group>
          <group group_id="O3">
            <title>Linezolid-oral From Injection</title>
            <description>Participants with who have been treated with Linezolid by orally from injection .</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Safety of Linezolid - Route of Administration.</title>
          <description>Number of participants Route of administration as by oral,injection or oral from injection with adverse drug reaction to determine whether oral, injection or switch is significant risk factor.</description>
          <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="768"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Route of administration&quot;. The null hypothesis is there is no difference between &quot;oral, injection and switch&quot; in the incidence rate of ADRs.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.018</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Factors Considered to Affect the Safety of Linezolid - Weight.</title>
        <description>Number of participants Weight as over 40kg or less than 40kg with adverse drug reaction to determine whether over 40kg or less than 40kg Weight is significant risk factor.</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid -Over 40kg</title>
            <description>Participants over 40kg who have been treated with Linezolid.</description>
          </group>
          <group group_id="O2">
            <title>Linezolid -Less Than 40kg</title>
            <description>Participants less than 40kg who have been treated with Linezolid.</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Safety of Linezolid - Weight.</title>
          <description>Number of participants Weight as over 40kg or less than 40kg with adverse drug reaction to determine whether over 40kg or less than 40kg Weight is significant risk factor.</description>
          <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="651"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Weight&quot;. The null hypothesis is there is no difference between &quot;over 40kg and less than 40kg&quot; in the incidence rate of ADRs.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.311</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Factors Considered to Affect the Safety of Linezolid - Concomitant Drugs.</title>
        <description>Number of participants with or without Concomitant drugs with adverse drug reaction to determine whether with or without is significant risk factor.</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid-without Concomitant Drugs</title>
            <description>Participants without Concomitant drugs who have been treated with Linezolid.</description>
          </group>
          <group group_id="O2">
            <title>Linezolid-with Concomitant Drugs</title>
            <description>Participants with Concomitant drugs who have been treated with Linezolid.</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Safety of Linezolid - Concomitant Drugs.</title>
          <description>Number of participants with or without Concomitant drugs with adverse drug reaction to determine whether with or without is significant risk factor.</description>
          <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="873"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Concomitant drugs&quot;. The null hypothesis is there is no difference between &quot;with Concomitant drug and without Concomitant drug&quot; in the incidence rate of ADRs.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.044</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Factors Considered to Affect the Safety of Linezolid - Non-drug Therapies.</title>
        <description>Number of participants with or without Non-drug therapies with adverse drug reaction to determine whether with or without is significant risk factor.</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid-without Non-drug Therapies</title>
            <description>Participants without Non-drug therapies who have been treated with Linezolid.</description>
          </group>
          <group group_id="O2">
            <title>Linezolid-with Non-drug Therapies</title>
            <description>Participants with Non-drug therapies who have been treated with Linezolid.</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Safety of Linezolid - Non-drug Therapies.</title>
          <description>Number of participants with or without Non-drug therapies with adverse drug reaction to determine whether with or without is significant risk factor.</description>
          <population>Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="610"/>
                <count group_id="O2" value="360"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Non-drug therapies&quot;. The null hypothesis is there is no difference between &quot;with Non-drug therapies and without Non-drug therapies&quot; in the incidence rate of ADRs.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.008</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Linezolid</title>
          <description>Participants who have been treated with Linezolid.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA/J13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Superinfection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA/J13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Superinfection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="78" subjects_affected="78" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Antithrombin III decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Blood chloride increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Reticulocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="970"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="970"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

